

Irfan Khan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7100487/irfan-khan-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

649
citations

13
h-index

25
g-index

29
ext. papers

850
ext. citations

5.3
avg, IF

3.91
L-index

#	Paper	IF	Citations
27	A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 472-89	4.9	154
26	Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017 , 2, 959-966	16.2	77
25	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. <i>Circulation</i> , 2019 , 139, 1603-1611	16.1	54
24	The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 179-186	3.9	52
23	Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. <i>Atherosclerosis</i> , 2016 , 251, 248-254	3.1	48
22	Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1109-18	4.9	43
21	Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. <i>Clinical Therapeutics</i> , 2017 , 39, 819-827.e1	3.5	34
20	Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population. <i>Clinical Cardiology</i> , 2017 , 40, 155-162	3.3	29
19	Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. <i>JAMA Cardiology</i> , 2019 , 4, 375-379	16.2	24
18	Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. <i>BMJ Open</i> , 2017 , 7, e013255	3	23
17	Association of cinacalcet adherence and costs in patients on dialysis. <i>Journal of Medical Economics</i> , 2011 , 14, 798-804	2.4	20
16	Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1680-1681	15.1	15
15	Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008. <i>American Journal of Kidney Diseases</i> , 2010 , 55, 113-20	7.4	15
14	Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2019 , 123, 1202-1207	3	9
13	Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. <i>Current Medical Research and Opinion</i> , 2010 , 26, 2679-87	2.5	9
12	Development and Content Validity Testing of a Patient-Reported Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection. <i>Value in Health</i> , 2015 , 18, 1000-7	3.3	8
11	Psychometric Evaluation of a Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection. <i>Value in Health</i> , 2017 , 20, 430-440	3.3	6

10	Risk of Incident Atherosclerotic Cardiovascular Disease Events by Achieved Atherogenic Lipid Levels Among 62,428 Statin-Treated Individuals With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2018 , 122, 762-767	3	5
9	Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2019 , 216, 30-41	4.9	4
8	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. <i>Journal of the American Heart Association</i> , 2020 , 9, e016506	6	4
7	Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis. <i>BMC Nephrology</i> , 2011 , 12, 22	2.7	3
6	Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239,234 Patients During 2005 to 2018 in the United States.. <i>Journal of the American Heart Association</i> , 2022 , e022198	6	3
5	RECURRENT CARDIOVASCULAR EVENT RATES IN A CONTEMPORARY COHORT OF 829,498 ADULTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 59	15.1	2
4	Prevalence of Atherosclerotic Cardiovascular Disease (ASCVD) and Diabetes Populations in the United States. <i>Journal of Clinical Lipidology</i> , 2015 , 9, 424	4.9	2
3	Simulation Models of Therapy Intensification in Lipid-Lowering Medicine-Reply. <i>JAMA Cardiology</i> , 2018 , 3, 89	16.2	1
2	Calibration and Uncertainty in Neural Time-to-Event Modeling. <i>IEEE Transactions on Neural Networks and Learning Systems</i> , 2020 , PP,	10.3	1
1	Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease. <i>American Journal of Medicine</i> , 2020 , 133, 200-206	2.4	1